LifeMD (LFMD) CMO reports sale of 15,000 shares at $3.6105 average price

Rhea-AI Filing Summary

LifeMD, Inc. reported that its Chief Marketing Officer, Jessica Friedeman, sold 15,000 shares of common stock on 12/09/2025 at a weighted average price of $3.6105 per share. The sale was executed through multiple transactions at prices ranging from $3.585 to $3.645.

Following this transaction, she beneficially owns 205,000 shares of LifeMD common stock, held directly. This disclosure describes a personal stock transaction by a senior executive and does not itself indicate any change in LifeMD’s business operations or financial results.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRIEDEMAN JESSICA

(Last) (First) (Middle)

C/O LIFEMD

236 FIFTH AVENUE, SUITE 400

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LifeMD, Inc. [ LFMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		S		15,000	D	$3.6105(1)	205,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.585 to $3.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth.

	/s/ Jessica Friedeman	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for LifeMD (LFMD) on 12/09/2025?

The report shows that Jessica Friedeman, Chief Marketing Officer of LifeMD, Inc., sold 15,000 shares of LifeMD common stock on 12/09/2025 at a weighted average price of $3.6105 per share.

Who is the LifeMD (LFMD) insider involved in this stock sale?

The insider is Jessica Friedeman, who serves as Chief Marketing Officer of LifeMD, Inc. and is identified as an officer of the company.

How many LifeMD (LFMD) shares does the insider own after the sale?

After the reported transaction, Jessica Friedeman beneficially owns 205,000 shares of LifeMD common stock, with the ownership reported as direct.

At what prices were the LifeMD (LFMD) shares sold in this insider transaction?

The filing states that the 15,000 shares were sold in multiple trades at prices ranging from $3.585 to $3.645 per share, with a weighted average sale price of $3.6105.

What SEC form reports this LifeMD (LFMD) insider stock sale?

The transaction is disclosed on a Form 4, which is filed under Section 16(a) of the Securities Exchange Act of 1934 to report changes in the beneficial ownership of a company’s securities by insiders.

Is this LifeMD (LFMD) insider transaction reported by one person or multiple insiders?

The disclosure indicates that the Form 4 is filed by one reporting person, specifically covering the transactions of Jessica Friedeman.